Two randomized placebo-controlled trials reported a significant response and prolonged progression-free survival (PFS) after the incorporation of bevacizumab, an anti-VEGF monoclonal antibody, into the primary chemotherapy regimen for ovarian cancer patients (Burger et al. 2011; Perren et al. 2011). This evidence concerns the gene VEGFA and ovarian cancer.